NEW YORK, NY / ACCESSWIRE / January 24, 2021 /The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
Boston Scientific Corporation (NYSE: BSX)
Investors Affected : April 24, 2019 - November 16, 2020
A class action has commenced on behalf of certain shareholders in Boston Scientific Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the LOTUS Edge Aortic Valve System's product delivery system was dysfunctional and threatened the continued viability of the entire product line; (ii) as a result, the Company had materially overstated the continued commercial viability and profitability of the LOTUS Edge Aortic Valve System; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://securitiesclasslaw.com/securities/boston-scientific-corporation-loss-submission-form/?id=12381&from=1
GoodRx Holdings, Inc (NASDAQ: GDRX)
Investors Affected : September 23, 2020 - November 16, 2020
A class action has commenced on behalf of certain shareholders in GoodRx Holdings, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: at the time of the IPO, unbeknownst to investors, Amazon.com, Inc. was developing and would soon introduce its own online and mobile prescription medication ordering and fulfillment service that would directly compete with GoodRx. Defendants timed the IPO so that it was priced before Amazon announced its online pharmaceutical business to facilitate the IPO and create artificial demand for the common shares sold therein, as well to maximize the amount of money the Company and the selling stockholders could raise in the IPO. Given defendants' knowledge of Amazon's intention to enter the online pharmaceutical business, and their misleading statements about GoodRx's competitive position made contemporaneously with that knowledge, defendants' materially false and/or misleading statements alleged herein were made willfully and caused GoodRx common stock to trade at artificially inflated prices during the Class Period.
Shareholders may find more information at https://securitiesclasslaw.com/securities/goodrx-holdings-inc-loss-submission-form/?id=12381&from=1
Cleanspark, Inc. (NASDAQ: CLSK)
Investors Affected : December 31, 2020 - January 14, 2021
A class action has commenced on behalf of certain shareholders in Cleanspark, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) that the Company had overstated its customer and contract figures; (2) that several of the Company's recent acquisitions involved undisclosed related party transactions; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Shareholders may find more information at https://securitiesclasslaw.com/securities/cleanspark-inc-loss-submission-form/?id=12381&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE:The Gross Law Firm
View source version on accesswire.com:
© 2021 Accesswire. All Rights Reserved.